Woodcock: FDA may have misstepped before Alzheimer’s drug approval – STAT
WASHINGTON Acting Food and Drug Administration Commissioner Janet Woodcock acknowledged on Wednesday her agency may have misstepped in its handling of its polarizing approval of a new Alzheimers drug.
She was emphatic in her defense of the therapy and the…
